ClinicalTrials.gg
TerminatedNCT01893359Updated Apr 26, 2021Results posted

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

A Phase 1/2 interventional study of riboflavin ophthalmic solution, 0% dextran and UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA) in Hyperopia and Hyperopic Astigmatism, sponsored by Glaukos Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by Glaukos Corporation · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Hyperopia with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Hyperopia · United States.

Enrollment
54th of 54
2 · median 61
Started
2013
with 1 other
Phase 1/2
4 of 68
none open now
Registered
22nd of 68
by date

Among the 68 studies in Hyperopia with a site in United States, this one is the 54th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 1/2, and was the 22nd registered.

Hyperopia

156 studies on the registry are indexed under Hyperopia; 20 are open to participants now.

Browse Hyperopia studies →

Open to participants now

3 of the 68 studies in Hyperopia with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Hyperopia studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hyperopia with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety and efficacy, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (MRSE), of two treatment regimens for hyperopic and hyperopic astigmatic subjects: LASIK followed by cross-linking performed with the KXL System and Photrexa ZD™ (Riboflavin Ophthalmic Solution), as compared to LASIK alone.

03

Conditions studied

  • Hyperopia
  • Hyperopic Astigmatism

Keywords

  • hyperopia
  • hyperopic astigmatism
  • cross-linking
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Be at least 18 years of age, male or female, of any race;
    1. Provide written and sign a HIPAA form;
    1. Willingness and ability to follow all instructions and comply with the schedule for study visits;
    1. Undergoing bilateral LASIK for the correction of hyperopia or hyperopic astigmatism;
    1. Intended treatment > +2.0 diopters (D) to \< +6.0 D of MRSE hyperopia or hyperopia with astigmatism, with up to +6.0 D of spherical component and up to 5.0 D of astigmatic component (all refractions measured at the spectacle plane);
    1. Bilateral physiologic hyperopia;
    1. For females capable of becoming pregnant, agree to have urine pregnancy testing performed at visit 2 prior to treatment; must not be lactating, and must agree to use a medically acceptable form of for at least one week prior to the visit 2 and continue to use the method for one month following the treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
    1. Best spectacle corrected visual acuity (BSCVA) of 70 letters or more on ETDRS chart;
    1. Difficulty maintaining uncorrected visual acuity (UCVA) of at least 70 letters on ETDRS chart as evidenced by need for constant contact lens or spectacle wear;
    1. Less than 0.75 D spherical equivalent difference between cycloplegic and manifest refractions;
    1. Stable refraction (a difference of 0.50 D or less in MRSE) for the last 12 months, objectively documented (by previous clinical records, prescriptions, etc.), exclusive of changes determined by the investigator to be due to unmasking latent hyperopia;
    1. Normal corneal topography, as judged by the investigator;
    1. Removal of contact lenses for the required period of time prior to the screening refraction:

      1. Soft - 3 Days
      2. Soft Toric - 2 Weeks
      3. Rigid gas permeable - 2 Weeks
    1. Contact Lens Wearers Only: Must demonstrate a stable refraction (a difference of 0.50 D or less) as determined by MRSE on two consecutive exam dates performed at least 7 days apart. A contact lens wearer is defined as someone who has worn contact lenses in either eye in the last 30 days.

Exclusion criteria

Exclusion Criteria:

    1. , sensitivity or known allergy to the use of the test article(s) or their components;
    1. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test at Visit 2 prior to treatment or during the course of the study;
    1. Eyes which are aphakic;
    1. Eyes which are pseudophakic and do not have a UV blocking lens implanted;
    1. Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study (e.g., dry eyes, immuno- compromised, connective tissue disease, atopic disease, diabetes, etc.);
    1. Systemic medications that may confound the outcome of the study or increase the risk to the subject, including but not limited to , antimetabolites, etc.;
    1. Ocular condition that may predispose the subject to future complications, for example:

      1. History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal dystrophy, etc.);
      2. Evidence of retinal vascular disease;
      3. Keratoconus or keratoconus suspect;
      4. Glaucoma or glaucoma suspect by exam findings and/or family history;
    1. Previous intraocular or corneal surgery including prior refractive surgery that might confound the outcome of the study or increase the risk to the subject;
    1. An increased risk for developing strabismus post-treatment;
    1. Subjects with nystagmus or any other condition that would prevent a steady gaze during treatment or other diagnostic tests;
    1. Taking supplements containing Vitamin C (ascorbic acid) within 1 week of the cross-linking treatment;
    1. Corneal thickness \<470 microns as measured by Pentacam;
    1. The Investigator may exclude or discontinue any subject for any sound medical reason;
    1. The subject should not have participated in any drug or device study within 30 days of screening or be concurrently enrolled in another investigational drug or device study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    LASIK followed by Cross-linking (Continuous Wave)

    Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.

    Drug: riboflavin ophthalmic solution, 0% dextran · Device: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA) · Procedure: Laser-assisted in situ keratomileusis

  • Experimental
    LASIK followed by Cross-linking (Pulsed)

    Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.

    Drug: riboflavin ophthalmic solution, 0% dextran · Device: UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off) · Procedure: Laser-assisted in situ keratomileusis

  • Placebo comparator
    LASIK Only

    Eyes assigned to this arm will receive standard LASIK with no cross-linking.

    Procedure: Laser-assisted in situ keratomileusis

Interventions

  • Drugriboflavin ophthalmic solution, 0% dextran

    Drug pages: Riboflavin · Dextrans

    Also known as: Photrexa ZD

  • DeviceUVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)

    Also known as: KXL System

  • DeviceUVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)

    Also known as: KXL System

  • ProcedureLaser-assisted in situ keratomileusis

    Also known as: LASIK

06

What researchers measure

Primary outcomes

  1. MRSE Regression

    The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.

    Time frame: one week to six months

  2. MRSE Regression

    The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.

    Time frame: one week to twelve months

07

Results

Posted Oct 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneLASIK Followed by Cross-linking (Continuous Wave)LASIK Followed by Cross-linking (Pulsed)LASIK Only
Started020
Completed020
Not completed000

Outcome measures

PrimaryMRSE Regression

The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.

Time frame:
one week to six months

No measurements were reported for this outcome.

PrimaryMRSE Regression

The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.

Time frame:
one week to twelve months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LASIK Followed by Cross-linking (Continuous Wave)———
LASIK Followed by Cross-linking (Pulsed)—0/2 (0%)2/2 (100%)
LASIK Only——2/2 (100%)
Most frequent other events
Most frequent other events
EventLASIK Followed by Cross-linking (Continuous Wave)LASIK Followed by Cross-linking (Pulsed)LASIK Only
Vision blurredEye disorders—1/21/2
Foreign body sensation in eyeEye disorders—1/21/2
PhotophobiaEye disorders—1/21/2
Conjunctival hyperaemiaEye disorders—0/21/2
Dry eyeEye disorders—0/21/2
Eye irritationEye disorders—1/20/2
Corneal flap complicationInjury, poisoning and procedural complications—1/21/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LASIK Followed by Cross-linking (Continuous Wave)LASIK Followed by Cross-linking (Pulsed)LASIK OnlyTotal
<=18 years—0—0
Between 18 and 65 years—2—2
>=65 years—0—0
Sex: Female, Male
Sex: Female, Male(Participants)LASIK Followed by Cross-linking (Continuous Wave)LASIK Followed by Cross-linking (Pulsed)LASIK OnlyTotal
Female—1—1
Male—1—1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LASIK Followed by Cross-linking (Continuous Wave)LASIK Followed by Cross-linking (Pulsed)LASIK OnlyTotal
American Indian or Alaska Native—0—0
Asian—0—0
Native Hawaiian or Other Pacific Islander—0—0
Black or African American—0—0
White—2—2
More than one race—0—0
Unknown or Not Reported—0—0
08

Study locations

5 sites
  • Gordon -Weiss-Schanzlin Vision Institute
    San Diego, California 92122, United States
  • Ophthalmic Consultants of Boston
    Waltham, Massachusetts 02451, United States
  • Hersh Vision Group
    Teaneck, New Jersey 07666, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57108, United States
  • See Clearly Vision
    McLean, Virginia 22102, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2013
First posted
Jul 9, 2013
Start
Aug 2013
Primary completionActual
Feb 2015
CompletionActual
Apr 2016
Results first posted
Oct 24, 2016
Last update
Apr 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01893359
Responsible party
Sponsor
First posted
Jul 9, 2013
Start date
Aug 2013
Primary completion
Feb 2015
Completion
Apr 2016
Results posted
Oct 24, 2016
Last update
Apr 26, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Riboflavin · Dextrans

Start the discussion